Workflow
中医药守正创新
icon
Search documents
同仁堂科技闪耀中医大会:亮出“守正创新”硬核答卷
经典名方守护健康 在此次中医大会上,同仁堂科技公司携带西黄丸、京制牛黄解毒片、六味地黄丸、生脉饮、壮腰健肾 丸、养血荣筋丸、感冒清热颗粒、儿药系列等二十余个大品种亮相,覆盖了抗癌、补益、肾病、清热解 毒等门类,其中不少还是家庭药箱中常备产品。 9月12日至14日,同仁堂集团举办第三届中医大会,成为中医药学术交流的高端平台。在此次展会上, 北京同仁堂科技发展股份有限公司(以下简称"同仁堂科技公司")携旗下众多经典产品与创新成果重磅 亮相。从覆盖全生命周期的"六维产品矩阵"到"非遗"炮制技艺,再到一系列基于实验室数据的硬核科研 成果,公司全方位展示了其秉承"遵古不泥古,创新不离宗"的理念,持续推动中医药守正创新与高质量 发展的实力与担当。 产品矩阵全维亮相 丰富的产品门类吸引了不少医生与研究者驻足参观,一名社区卫生站的大夫说道:"很多人得了风寒感 冒,到我这里开药,点名就要同仁堂的感冒清热颗粒。" 目前,科技公司围绕旗下两百多个中成药产品,构建"大品种、中线品种、御药品种、国药精品、阿胶 系列、儿药系列"六维产品矩阵,"针对症候与使用场景,适配不同产品,让企业品种都能找到服务消费 者的'赛道'。"企业相关负责人表 ...
雷允上苏合香丸狂飙突进,经典名方撬动现代医药市场新机遇
21世纪经济报道· 2025-03-21 12:26
Core Viewpoint - The article highlights the significant growth and market dominance of Suhexiang Wan, a traditional Chinese medicine, in the cardiovascular disease prevention and treatment sector, driven by policy support and modern clinical research [2][3]. Group 1: Market Performance - Suhexiang Wan's sales in urban public hospitals increased from 42.08 million yuan in 2020 to 558 million yuan in 2023, while retail sales in urban pharmacies rose from 232,000 yuan to 8.2 million yuan by 2024 [1]. - In the first half of 2024, Lei Yun Shang's Suhexiang Wan held a market share of approximately 75.15% in urban public medical institutions, with a retail growth rate of 236%, significantly outpacing competitors like Pian Zai Huang and Gui Ling Ji [1][3]. Group 2: Clinical and Retail Insights - Suhexiang Wan has been widely applied in clinical settings, covering nearly 3,000 hospitals and demonstrating effectiveness in emergency cases and cardiovascular disease prevention [4]. - The product's clear efficacy and modern adaptation have contributed to its retail success, contrasting with the slower growth of other traditional medicines like An Gong Niu Huang Wan and Gui Ling Ji, which saw declines in sales [5][6]. Group 3: Policy and Industry Trends - The Chinese government has intensified support for traditional Chinese medicine, with the "14th Five-Year Plan for Traditional Chinese Medicine Development" emphasizing the development and clinical application of classic formulas like Suhexiang Wan [6]. - The demand for cardiovascular health products is surging, with 81.7% of respondents in a health survey willing to invest more in health, indicating a growing market for traditional Chinese medicine [6][7]. Group 4: Competitive Landscape - The market for cardiovascular traditional Chinese medicine has expanded significantly, with total sales increasing from 5.216 billion yuan in 2017 to 10.083 billion yuan in 2024, nearly doubling [3]. - Suhexiang Wan's competitive edge is reinforced by its strong clinical evidence and market positioning, as it continues to capture a larger share of the growing demand for cardiovascular treatments [8].